albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
However, in a preprint study, Carnegie Mellon University researchers tested the behavior of agents in a simulated software company and found that none of the agents could complete a majority of the tasks assigned to them. Other researchers had similar findings with Devin AI and other agents in both formal business settings and freelance work. In June 2025, CNN argued that CEOs's statements on AI replacing their employees were a strategy to "[keep] workers working by making them afraid of losing their jobs." Tech companies have pressured employees to use generative AI models in their work, including AI coding agents. Brian Armstrong, the CEO of Coinbase, fired several employees who did not. Some business leaders have replaced some of their employees with agents, but have said that the agents would need more supervision than those employees. In October 2025, Futurism questioned whether Amazon's previously announced efforts to replace parts of its workforce with generative AI and AI agents could have led to the October 2025 outage of Amazon Web Services. Large technology companies such as Salesforce, Klarna and IBM announced layoffs in 2025, replacing hundreds of their employees in human resources or customer service with AI agents. However, Klarna later rehired several human employees. Yoshua Bengio warned at the 2025 World Economic Forum that "all of the catastrophic scenarios with AGI or superintelligence happen if we have agents". Financial authorities have warned that more complex and autonomous "agentic" AI could become a channel for systemic risk in finance.
The Menagerie is the second-oldest public zoo in the world still in operation, following the Tiergarten Schönbrunn in Vienna founded in 1752. It occupies the northeast side of the garden along the Quai St. Bernard, covering 5 hectares (12 acres). It was created between 1798 and 1836 as a home for the animals of the royal menagerie at Versailles, which were largely abandoned after the French Revolution. Its architecture features picturesque "fabriques", or pavilions, mostly created in the 19th century, to shelter the animals. In the 20th century the larger animals were moved to the Paris Zoological Park, a more extensive site in the Bois de Vincennes. also governed by the MNHN. The menagerie is currently home to about six hundred mammals, birds, reptiles, amphibians and invertebrates, representing about 189 species. These include the Amur leopard, one of the rarest cats on earth.
This is a list of standalone video games that have been ported from a modification of another video game, and/or that are entirely based on a modification of another video game. A game is considered standalone when it does not require the purchase or installation of any other game (including separate engine software such as the Source SDK) in order to run.
Typically, these projects make use of re-coded nonsense suppressor tRNA-Aminoacyl tRNA synthetase pairs from other organisms, though in most cases substantial engineering is required. Other researchers investigated protein structure and function by reducing the normal set of 20 amino acids. Limited protein sequence libraries are made by generating proteins where groups of amino acids may be replaced by a single amino acid. For instance, several non-polar amino acids within a protein can all be replaced with a single non-polar amino acid. One project demonstrated that an engineered version of Chorismate mutase still had catalytic activity when only nine amino acids were used. Researchers and companies practice synthetic biology to synthesize industrial enzymes with high activity, optimal yields and effectiveness. These synthesized enzymes aim to improve products such as detergents and lactose-free dairy products, as well as make them more cost effective. The improvements of metabolic engineering by synthetic biology is an example of a biotechnological technique utilized in industry to discover pharmaceuticals and fermentive chemicals. Synthetic biology may investigate modular pathway systems in biochemical production and increase yields of metabolic production. Artificial enzymatic activity and subsequent effects on metabolic reaction rates and yields may develop "efficient new strategies for improving cellular properties ... for industrially important biochemical production".
Sources: en.wikipedia.org
Charles's law appears to imply that the volume of a gas will descend to zero at a certain temperature (−266.66 °C according to Gay-Lussac's figures) or −273.15 °C. Gay-Lussac was clear in his description that the law was not applicable at low temperatures:
Carbon dioxide in the form of dry ice is often used during the cold soak phase in winemaking to cool clusters of grapes quickly after picking to help prevent spontaneous fermentation by wild yeast. The main advantage of using dry ice over water ice is that it cools the grapes without adding any additional water that might decrease the sugar concentration in the grape must, and thus the alcohol concentration in the finished wine. Carbon dioxide is also used to create a hypoxic environment for carbonic maceration, the process used to produce Beaujolais wine. Carbon dioxide is sometimes used to top up wine bottles or other storage vessels such as barrels to prevent oxidation, though it has the problem that it can dissolve into the wine, making a previously still wine slightly fizzy. For this reason, other gases such as nitrogen or argon are preferred for this process by professional wine makers.
A person, who is independent of the trial, who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the subject or the subject's legally acceptable representative cannot read, and who reads the informed consent form and any other written information supplied to the subject. (ICH E6) In vitro
=== Africa === The soybean first arrived in Africa via Egypt in 1857. Soya Meme (Baked Soya) is produced in the village called Bame Awudome near Ho, the capital of the Volta Region of Ghana, by the Ewe people of Southeastern Ghana and southern Togo.
== Live performances == The members of Rush shared a strong work ethic, desiring to accurately recreate songs from their albums when playing live performances. To achieve this goal, beginning in the late 1980s, Rush included a capacious rack of digital samplers in their concert equipment to recreate the sounds of non-traditional instruments, accompaniments, vocal harmonies, and other sound "events" in real time to match the sounds on the studio versions of the songs. In live performances, the band members shared duties throughout most songs. Each member had one or more MIDI controllers, which were loaded with different sounds for each song, and they used available limbs to trigger the sounds while simultaneously playing their primary instrument(s). With this technology the group was able to present their arrangements in a live setting with the level of complexity and fidelity fans had come to expect, and without the need to resort to the use of backing tracks or employing an additional band member during their initial run. The members' coordinated use of pedal keyboards and other electronic triggers to "play" sampled instruments and audio events was subtly visible in their live performances, especially on the R30: 30th Anniversary World Tour, their 2005 concert DVD. A staple of Rush's concerts was Neil Peart's drum solos, which included a basic framework of routines connected by sections of improvisation, making each performance unique. Each successive tour saw his solos become more advanced, with some routines dropped in favour of newer, more complex ones.
Sources: en.wikipedia.org
== Stages of progress in nanotechnology == In 2005, Mihail Roco, one of the architects of the USA's National Nanotechnology Initiative, proposed four states of nanotechnology that seem to parallel the technical progress of the Industrial Revolution, of which productive nanosystems is the most advanced. 1. Passive nanostructures - nanoparticles and nanotubes that provide added strength, electrical and thermal conductivity, toughness, hydrophilic/phobic and/or other properties that emerge from their nanoscale structure. 2. Active nanodevices - nanostructures that change states in order to transform energy, information, and/or to perform useful functions. There is some debate about whether or not state-of-the art integrated circuits qualify here, since they operate despite emergent nanoscale properties, not because of them. Therefore, the argument goes, they don't qualify as "novel" nanoscale properties, even though the devices themselves are between one and a hundred nanometers. 3. Complex nanomachines - the assembly of different nanodevices into a nanosystem to accomplish a complex function. Some would argue that Zettl's machines fit in this category; others argue that modern microprocessors and FPGAs also fit. 4. Systems of nanosystems/Productive nanosystems - these will be complex nanosystems that produce atomically precise parts for other nanosystems, not necessarily using novel nanoscale-emergent properties, but well-understood fundamentals of manufacturing. Because of the discrete (i.e.
==== Symptoms ==== Necrosis may be symptomatic or asymptomatic. Symptomatic necrosis involves lingering pain response to hot and cold stimuli, spontaneous pain that may cause a patient to awaken during sleep, difficulty eating and sensitivity to percussion. Asymptomatic necrosis is non-responsive to thermal stimuli or electric pulp tests, leaving the patient unaware of the pathology.
== Clinical significance == There are many diseases where failure to adequately absorb iron contributes to iron deficiency and iron deficiency anemia. The treatment will depend on the hepcidin levels that are present, as oral treatment will be unlikely to be effective if hepcidin is blocking enteral absorption; in these cases, parenteral iron treatment would be appropriate. Studies have found that measuring hepcidin would help establish the optimal treatment for a patient, but as this is not widely available, C-reactive protein (CRP) is used as a surrogate marker. Chronic alcohol consumption can lead to excess iron accumulation in the liver, which may contribute to the development of alcoholic liver disease. Chronic alcohol use may increase iron accumulation by inhibiting hepcidin gene expression. The main mechanisms appear to be increasing oxidative stress through its metabolite acetaldehyde, and by inhibiting the release of interleukin 6 (IL-6) from macrophages; each of these actions reduce the expression and DNA-binding activity of the transcription factor C/EBPα, which would otherwise stimulate hepcidin expression. Beta thalassemia, one of the most common congenital anemias, arises from partial or complete failure to synthesize beta-globin, a component of hemoglobin. Excessive iron absorption is one of the main features of beta thalassemia and can lead to severe morbidity and mortality.
As of 2018, the city has been ranked by GaWC as a Gamma-level global city. Turin is home to much of the Italian automotive industry, and is the base for the headquarters of Fiat, Lancia, and Alfa Romeo. The city has a rich culture and history, and is known for its numerous art galleries, restaurants, churches, palaces, opera houses, piazzas, parks, gardens, theatres, libraries, museums and other venues. Turin is well known for its Baroque, Rococo, Neoclassical, and Art Nouveau architecture. Many of Turin's public squares, castles, gardens, and elegant palazzi, such as the Palazzo Madama, were built between the 16th and 18th centuries. A part of the historical centre of Turin was inscribed in the World Heritage List under the name Residences of the Royal House of Savoy. In addition, the city is home to museums, such as the Museo Egizio, and the Mole Antonelliana, the city's architectural symbol, which in turn hosts the National Museum of Cinema. Turin's attractions make it one of the world's top 250 tourist destinations and the tenth-most visited city in Italy in 2008. The city also hosts some of Italy's most important universities, colleges, academies, lycea, and gymnasia, such as the University of Turin, founded in the 15th century, and the Turin Polytechnic. Turin is also famous worldwide for icons such as the Shroud of Turin, the gianduiotto, the automobile brand Fiat, and the association football club Juventus, which competes with its rival Torino in the Derby della Mole, the city's derby.
=== Amino-acid shuttles and the transport of ammonia === Since diffusion and transport of free ammonia across the cell membrane will affect the pH level of the cell, the more attractive and regulated way of transporting ammonia between the neuronal and the astrocytic compartment is via an amino-acid shuttle, of which there are two: leucine and alanine. The amino acid moves in the opposite direction of glutamine. In the opposite direction of the amino acid, a corresponding molecule is transported; for alanine this molecule is lactate; for leucine, α-ketoisocaproate.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.